| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 The University of Texas M. D. Anderson Cancer Center, Houston, Texas; 2 Dana Farber Cancer Institute, Boston, Massachusetts; 3 Washington University, St. Louis, Missouri; 4 Fox Chase Cancer Center, Philadelphia, Philadelphia; and 5 Massachusetts General Hospital, Boston, Massachusetts
Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened 137 tumors for HER2 expression.
Experimental Design: Unstained sections of paraffin-embedded tumor samples were stained with p185/HER2 receptor antibody. Tumors with moderate (2+) to strong (3+) complete membrane staining in at least 10% of the tumor cells were scored as positive for overexpression.
Results: The overall frequency of overexpression for HER2 was 17% (23 of 137), whereas it was only 8% in the three most common histological subtypes screened. Overexpression was distinctly rare in the most common subtype screened, adenoid cystic carcinoma (4%, 3 of 70). Overexpression was very common in salivary duct cancers; 10 (83%) of 12 were positive for HER2. This observation is consistent with the typical high-grade histological features and aggressive behavior of this subtype as well as with its histogenetic similarity to breast cancer. Analysis based on histogenesis (intercalated duct versus excretory duct) indicated a higher frequency of overexpression in the latter (55%) than in the former (7%).
Conclusions: Our overall results suggest that trastuzumab will not have a major role in treatment of salivary gland cancers of intercalated duct origin. Further systematic evaluation of trastuzumab in subtypes of excretory duct origin could be supported.
This article has been cited by other articles:
|
|
 |
|
  G. Cornolti, M. Ungari, M. L. Morassi, F. Facchetti, E. Rossi, D. Lombardi, and P. Nicolai Amplification and Overexpression of HER2/neu Gene and HER2/neu Protein in Salivary Duct Carcinoma of the Parotid Gland Arch Otolaryngol Head Neck Surg, October 1, 2007; 133(10): 1031 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Agulnik, E. W.E. Cohen, R. B. Cohen, E. X. Chen, E. E. Vokes, S. J. Hotte, E. Winquist, S. Laurie, D. N. Hayes, J. E. Dancey, et al. Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands J. Clin. Oncol., September 1, 2007; 25(25): 3978 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Williams, N. Chakravarti, M. S. Kies, S.-I. Maruya, J. N. Myers, J. C. Haviland, R. S. Weber, R. Lotan, and A. K. El-Naggar Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors Clin. Cancer Res., December 15, 2006; 12(24): 7353 - 7358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Laurie and L. Licitra Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers J. Clin. Oncol., June 10, 2006; 24(17): 2673 - 2678. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
